Leon Leticia, Redondo Marta, Garcia-Vadillo Alberto, Perez-Nieto Miguel A, Rodriguez-Rodriguez Luis, Jover Juan A, Gonzalez-Alvaro Isidoro, Abasolo Lydia
Rheumatology Department, IdISSC, Hospital Clinico San Carlos, Calle Profesor Martin Lagos S/N, 28040, Madrid, Spain.
Universidad Camilo José Cela, Madrid, Spain.
Rheumatol Int. 2016 Nov;36(11):1549-1555. doi: 10.1007/s00296-016-3561-9. Epub 2016 Sep 10.
Individualized treatment of rheumatoid arthritis (RA) based on genetic/serologic factors is increasingly accepted. Moreover, patients are more actively involved in the management of their disease. However, personality has received little attention with respect to perception of the need and adherence to treatment. Our objective was to evaluate whether patient personality was associated with the acceptance or rejection of more aggressive early treatment. We performed a cross-sectional study in two hospitals with early arthritis clinics where sociodemographic, clinical, and therapeutic variables are systematically recorded. Patients completed Eysenck Personality Questionnaire, Multidimensional Health Locus of Control, Pain-Related Self-Statement Scale and Pain-Related Control Scale. Aggressive treatment was considered if patients received more than two DMARDs or biological agents during the first year of follow-up. Multivariate logistic regression analysis was performed to determine predictors of aggressive treatment. One hundred seventy-six RA patients were included (80 % women, disease begin median age 55 years). Treatment was considered aggressive in 57.9 % of the sample. Scores were high in extraversion in 50.8 % of patients, neuroticism in 29.5 % and psychoticism in 14.7 %. Neuroticism was the only factor associated with aggressive treatment, which was less probable (p = 0.04, OR = 0.40). Neuroticism also decreased the possibility of receiving a combination of biologics and DMARDs (p = 0.04, OR = 0.28). Patients with high scores on neuroticism are more worried, obsessive and hypochondriac, leading them to reject more aggressive therapy. It is important to educate about their disease so that they will accept more aggressive approaches in clear cases of poor outcome.
基于遗传/血清学因素的类风湿关节炎(RA)个体化治疗越来越被认可。此外,患者在疾病管理中也更加积极主动。然而,在对治疗需求的认知和治疗依从性方面,人格因素很少受到关注。我们的目的是评估患者人格是否与接受或拒绝更积极的早期治疗有关。我们在两家设有早期关节炎诊所的医院进行了一项横断面研究,系统记录了社会人口学、临床和治疗变量。患者完成了艾森克人格问卷、多维健康控制点量表、疼痛相关自我陈述量表和疼痛相关控制量表。如果患者在随访的第一年接受了两种以上的改善病情抗风湿药(DMARDs)或生物制剂,则认为是积极治疗。进行多因素逻辑回归分析以确定积极治疗的预测因素。纳入了176例RA患者(80%为女性,疾病开始的中位年龄为55岁)。57.9%的样本被认为接受了积极治疗。50.8%的患者外向性得分高,29.5%的患者神经质得分高,14.7%的患者精神质得分高。神经质是与积极治疗相关的唯一因素,积极治疗的可能性较小(p = 0.04,比值比[OR]=0.40)。神经质也降低了接受生物制剂和DMARDs联合治疗的可能性(p = 0.04,OR = 0.28)。神经质得分高的患者更焦虑、强迫和疑病,导致他们拒绝更积极的治疗。对他们进行疾病教育很重要,以便在明确预后不良的情况下,他们会接受更积极的治疗方法。